Mosunetuzumab (SC)

Phase 2

Roche Holding AG (RHHBY)

Phase 2

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No Catalysts Found

No catalyst events have been recorded for this drug yet.

Competitive Landscape

1 competitor in Follicular Lymphoma

GMABepcoritamab

Phase 2

View Full Landscape

Drug Information

Target Indication

Follicular Lymphoma

Clinical Trial

NCT04246086

Last updated: 4/10/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Regulatory Approvals

EMA6/3/2022

Lunsumio

Lunsumio as monotherapy is indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) who have received at least two prior systemic therapies.

OrphanConditional

View on EMA

Drug Science

Mechanism of action & safety profile

Developer

RHHBY

Roche Holding AG

Biotechnology•Europe•NYSE

Related Pipeline

RO7204239Phase 3

Obesity

trastuzumab (Herceptin®)Phase 3

Breast Cancer

mycophenolate mofetil [CellCept]Phase 3

Myasthenia Gravis Generalised

LenvatinibPhase 3

Unresectable Hepatocellular Carcinoma

RO7239361Phase 3

Duchenne Muscular Dystrophy

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts